2025年 研究業績

英文

1. Imeglimin may affect hemoglobin A1c accuracy via prolongation of erythrocyte lifespan in patients with type 2 diabetes mellitus: insights from the INFINITY clinical trial. Osonoi T, Shirabe S, Saito M, Hosoya M, Watahiki N, Shiozawa N, Douguchi S, Ofuchi K, Katoh M. Front Endocrinol. 2025 Oct 24;16:1699591. doi: 10.3389/fendo.2025.1699591.
2. Switching from febuxostat to dotinurad, a novel selective urate reabsorption inhibitor, may substantially reduce serum urate levels, through URAT1 inhibition, potentially without adversely affecting ABCG2 function: findings from the SWITCH SURI study. Osonoi T, Shirabe S, Saito M, Hosoya M, Watahiki N, Douguchi S, Ofuchi K, Katoh M. Front Endocrinol. 2025 Oct 2;16:1655502. doi: 10.3389/fendo.2025.1655502.
3. Long-term safety and efficacy of imeglimin in Japanese individuals with type 2 diabetes and chronic kidney disease: A 52-week postmarketing clinical study (TWINKLE). Babazono T, Osonoi T, Okamoto H, Onishi Y, Nakamoto S, Kashima M, Kawanami D, Nakashima E, Watabe K, Nunami N, Hagi K. J Diabetes Investig. 2025 Oct;16(10):1808-1819. doi: 10.1111/jdi.70135.
4. Long-term efficacy and safety of early sitagliptin initiation in individuals with type 2 diabetes: an extension of the SPIKE study. Mita T, Katakami N, Yoshii H, Onuma T, Kaneto H, Osonoi T, Shiraiwa T, Yasuda T, Umayahara Y, Yamamoto T, Yokoyama H, Kuribayashi N, Matsumoto K, Gosho M, Shimomura I, Watada H. Diabetol Int. 2025 Jan 12;16(2):272-284. doi: 10.1007/s13340-024-00786-7.
5. Efficacy and safety of imeglimin add-on to DPP-4 inhibitor therapy in Japanese patients with type 2 diabetes mellitus: An interim analysis of the randomised, double-blind FAMILIAR trial. Kaku K, Shimoda M, Osonoi T, Iwamoto M, Kaneto H. Diabetes Obes Metab. 2025 Jun;27(6):3212-3222. doi: 10.1111/dom.16336.
6. Relationship of Carbohydrate Intake Proportion to Cardiovascular Events in Japanese People With Type 2 Diabetes Mellitus. Mita T, Osonoi Y, Someya Y, Osonoi T, Saito M, Nakayama S, Ishida H, Ishii R, Gosho M, Watada H. J Clin Endocrinol Metab. 2025 Oct 16;110(11):e3587-e3595. doi: 10.1210/clinem/dgaf179.